Meanwhile, multiple studies have shown that the clinical efficacy of PD-1 inhibitors depends on the quantity, quality, and tumor invasion characteristics of CD8+ T cells targeting mutation-associated tumor neoantigens (101, 102). Here, CD8A is linked to neoplasm.